Alector Inc (ALEC)

$6.49

Market is closed - opens 7 PM, 29 Jul 2024

Performance

  • $6.34
    $6.63
    $6.49
    downward going graph

    2.39%

    Downside

    Day's Volatility :4.45%

    Upside

    2.11%

    downward going graph
  • $3.66
    $9.07
    $6.49
    downward going graph

    43.61%

    Downside

    52 Weeks Volatility :59.65%

    Upside

    28.45%

    downward going graph

Returns

PeriodAlector IncSector (Health Care)Index (Russel 2000)
3 Months
23.62%
6.5%
0.0%
6 Months
7.45%
7.1%
0.0%
1 Year
3.67%
9.8%
0.0%
3 Years
-78.67%
14.2%
-20.2%

Highlights

Market Capitalization
610.1M
Book Value
$1.86
Earnings Per Share (EPS)
-1.39
Wall Street Target Price
13.75
Profit Margin
-125.11%
Operating Margin TTM
-275.01%
Return On Assets TTM
-13.13%
Return On Equity TTM
-66.65%
Revenue TTM
96.4M
Revenue Per Share TTM
1.12
Quarterly Revenue Growth YOY
-4.0%
Gross Profit TTM
-76.8M
EBITDA
-139.5M
Diluted Eps TTM
-1.39
Quarterly Earnings Growth YOY
-0.86
EPS Estimate Current Year
-1.96
EPS Estimate Next Year
-1.66
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.53

Analyst Recommendation

Buy
    76%Buy
    17%Hold
    5%Sell
Based on 17 Wall street analysts offering stock ratings for Alector Inc(by analysts ranked 0 to 5 stars)
Based on 17 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
13
14
14
Hold
3
3
3
Sell
1
1
1

Analyst Forecast

What analysts predicted

Upside of 111.86%

Current $6.49
Target $13.75

Company Financials

FY18Y/Y Change
Revenue
27.7M
↑ 641.02%
Net Income
-52.2M
↑ 60.86%
Net Profit Margin
-188.78%
↑ 680.83%
FY19Y/Y Change
Revenue
21.2M
↓ 23.33%
Net Income
-99.8M
↑ 91.03%
Net Profit Margin
-470.39%
↓ 281.61%
FY20Y/Y Change
Revenue
21.1M
↓ 0.57%
Net Income
-183.0M
↑ 83.31%
Net Profit Margin
-867.21%
↓ 396.82%
FY21Y/Y Change
Revenue
207.1M
↑ 881.54%
Net Income
-28.0M
↓ 84.69%
Net Profit Margin
-13.53%
↑ 853.68%
FY22Y/Y Change
Revenue
133.6M
↓ 35.48%
Net Income
-133.3M
↑ 375.87%
Net Profit Margin
-99.77%
↓ 86.24%
FY23Y/Y Change
Revenue
97.1M
↓ 27.36%
Net Income
-130.4M
↓ 2.19%
Net Profit Margin
-134.34%
↓ 34.57%
Q4 FY22Q/Q Change
Revenue
14.4M
↓ 2.77%
Net Income
-52.4M
↑ 13.61%
Net Profit Margin
-363.07%
↓ 52.35%
Q1 FY23Q/Q Change
Revenue
16.5M
↑ 14.61%
Net Income
-45.9M
↓ 12.53%
Net Profit Margin
-277.1%
↑ 85.97%
Q2 FY23Q/Q Change
Revenue
56.2M
↑ 239.68%
Net Income
1.4M
↓ 103.0%
Net Profit Margin
2.45%
↑ 279.55%
Q3 FY23Q/Q Change
Revenue
9.1M
↓ 83.8%
Net Income
-44.5M
↓ 3334.55%
Net Profit Margin
-488.25%
↓ 490.7%
Q4 FY23Q/Q Change
Revenue
15.2M
↑ 66.76%
Net Income
-41.4M
↓ 6.84%
Net Profit Margin
-272.77%
↑ 215.48%
Q1 FY24Q/Q Change
Revenue
15.9M
↑ 4.63%
Net Income
-36.1M
↓ 12.92%
Net Profit Margin
-227.01%
↑ 45.76%
FY18Y/Y Change
Total Assets
308.4M
↑ 30.63%
Total Liabilities
405.8M
↑ 40.84%
FY19Y/Y Change
Total Assets
421.9M
↑ 36.83%
Total Liabilities
227.2M
↓ 44.01%
FY20Y/Y Change
Total Assets
488.3M
↑ 15.72%
Total Liabilities
220.7M
↓ 2.84%
FY21Y/Y Change
Total Assets
814.7M
↑ 66.85%
Total Liabilities
513.9M
↑ 132.84%
FY22Y/Y Change
Total Assets
787.6M
↓ 3.32%
Total Liabilities
573.2M
↑ 11.53%
FY23Y/Y Change
Total Assets
621.8M
↓ 21.05%
Total Liabilities
487.7M
↓ 14.92%
Q4 FY22Q/Q Change
Total Assets
787.6M
↓ 5.9%
Total Liabilities
573.2M
↓ 1.84%
Q1 FY23Q/Q Change
Total Assets
748.3M
↓ 4.99%
Total Liabilities
565.3M
↓ 1.37%
Q2 FY23Q/Q Change
Total Assets
708.7M
↓ 5.29%
Total Liabilities
512.4M
↓ 9.36%
Q3 FY23Q/Q Change
Total Assets
672.4M
↓ 5.13%
Total Liabilities
509.8M
↓ 0.51%
Q4 FY23Q/Q Change
Total Assets
621.8M
↓ 7.52%
Total Liabilities
487.7M
↓ 4.35%
Q1 FY24Q/Q Change
Total Assets
635.5M
↑ 2.2%
Total Liabilities
456.6M
↓ 6.37%
FY18Y/Y Change
Operating Cash Flow
127.5M
↓ 817.26%
Investing Cash Flow
-224.1M
↑ 27879.9%
Financing Cash Flow
131.1M
↓ 874406.67%
FY19Y/Y Change
Operating Cash Flow
-99.3M
↓ 177.91%
Investing Cash Flow
-48.9M
↓ 78.19%
Financing Cash Flow
172.4M
↑ 31.42%
FY20Y/Y Change
Operating Cash Flow
-166.7M
↑ 67.9%
Investing Cash Flow
-105.1M
↑ 114.94%
Financing Cash Flow
232.1M
↑ 34.67%
FY21Y/Y Change
Operating Cash Flow
298.6M
↓ 279.06%
Investing Cash Flow
-49.7M
↓ 52.72%
Financing Cash Flow
30.3M
↓ 86.95%
FY22Y/Y Change
Operating Cash Flow
-20.3M
↓ 106.81%
Investing Cash Flow
-159.0M
↑ 220.19%
Financing Cash Flow
4.5M
↓ 85.1%
Q4 FY22Q/Q Change
Operating Cash Flow
-48.9M
↓ 0.26%
Investing Cash Flow
18.4M
↓ 69.63%
Financing Cash Flow
636.0K
↑ 30.06%
Q1 FY23Q/Q Change
Operating Cash Flow
-48.5M
↓ 0.77%
Investing Cash Flow
88.7M
↑ 382.57%
Financing Cash Flow
1.1M
↑ 69.65%
Q2 FY23Q/Q Change
Operating Cash Flow
-43.0M
↓ 11.42%
Investing Cash Flow
-21.8M
↓ 124.59%
Financing Cash Flow
881.0K
↓ 18.35%

Technicals Summary

Sell

Neutral

Buy

Alector Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Alector Inc
Alector Inc
50.23%
7.45%
3.67%
-78.67%
-69.08%
Moderna, Inc.
Moderna, Inc.
-1.67%
18.26%
-0.21%
-64.15%
752.69%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
-0.46%
13.21%
45.59%
84.19%
244.2%
Novo Nordisk A/s
Novo Nordisk A/s
-11.0%
18.31%
61.56%
186.46%
423.59%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
3.85%
14.43%
39.88%
147.45%
195.07%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Alector Inc
Alector Inc
15.47
NA
NA
-1.96
-0.67
-0.13
NA
1.86
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-7.19
-0.38
-0.16
NA
33.47
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
31.35
31.35
1.46
44.44
0.15
0.08
NA
250.15
Novo Nordisk A/s
Novo Nordisk A/s
44.28
44.28
2.36
3.43
1.0
0.25
0.01
22.18
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
31.85
31.85
0.53
16.98
0.24
0.13
NA
71.8
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Alector Inc
Alector Inc
Buy
$610.1M
-69.08%
15.47
-125.11%
Moderna, Inc.
Moderna, Inc.
Buy
$45.3B
752.69%
24.73
-115.82%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$116.9B
244.2%
31.35
29.45%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$572.0B
423.59%
44.28
36.55%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$126.7B
195.07%
31.85
39.46%

Insights on Alector Inc

  • Increasing Revenue

    Revenue is up for the last 3 quarters, 9.10M → 15.89M (in $), with an average increase of 22.2% per quarter

  • Increasing Net Profit

    Netprofit is up for the last 3 quarters, -44.47M → -36.07M (in $), with an average increase of 11.1% per quarter

  • Vs NVO

    In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 57.9%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 265.2%

Institutional Holdings

  • FMR Inc

    14.90%

  • BlackRock Inc

    8.80%

  • Vanguard Group Inc

    5.10%

  • EcoR1 Capital, LLC

    4.21%

  • State Street Corporation

    4.06%

  • Deep Track Capital, LP

    3.91%

Company Information

we are a biotech company based in san francisco dedicated to the discovery and development of novel therapies harnessing the power of immune system to treat neurodegenerative diseases such as alzheimer's disease.

Organization
Alector Inc
Employees
244
CEO
Dr. Arnon Rosenthal Ph.D.
Industry
Biotechnology

Discover More

FAQs